Pfizer seeks dismissal of Nigeria lawsuit

Pfizer has unveiled its defense in the Nigerian lawsuit over a clinical trial that allegedly killed 11 children and injured 189 others during a meningitis epidemic. The company says it actually saved lives by administering the experimental antibiotic Trovan. The children who died were victims of the disease itself, not the drug, the court filing states. Pfizer is asking the Nigerian court to throw out the lawsuits altogether.

Trovan has a checkered history: Initially a popular antibiotic in the U.S. and Europe, it was eventually severely restricted (in the States) or banned (in the EU). In the U.S., it was never approved by regulators for use in children. Filed in May, these four lawsuits charge that Pfizer didn't tell the sick children's families that they were participating in a trial. Nigeria is seeking $8.5 billion in penalties, plus pursuing criminal charges against the company and its executives and agents.

- see this article for more

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

The new Community trial will first test Amgen's Otezla, Takeda's Takhzyro and UCB's zilucoplan in hospitalized patients.

Indivior faces a new lawsuit from RB, its former parent company, over a scheme to market opioid addiction therapy Suboxone Film.

A new FDA effort brings cancer drug labels to life in videotaped panels with experts, debuting its first episode on Seagen's MBC med Tukysa.